Results 81 to 90 of about 3,514 (173)

Ten-Year Experience with Sevelamer and Calcium Salts as Phosphate Binders

open access: yes, 2010
Most patients with chronic kidney disease experience abnormalities in serum calcium, phosphorus, parathyroid hormone, and vitamin D metabolism.
WESSELING, Katherine   +9 more
core   +1 more source

Sulfonic acid-functionalized polyallylamine (sevelamer) as an efficient reusable strong solid acid catalyst for the synthesis of xanthenes derivatives

open access: yesBMC Chemistry, 2019
Sevelamer (polyallyamine resin)-supported sulfonic acid (S-SO3H) has been prepared from the reaction of sevelamer with chlorosulfonic acid and characterized using FT-IR spectroscopy, scanning electronmicroscopy (SEM) and thermogravimetric analysis (TGA).
Xian-Liang Zhao   +2 more
doaj   +1 more source

Biomechanical Properties of Bones from Rats Treated with Sevelamer

open access: yes, 2011
Sevelamer hydrochloride is used for ten years in patients on dialysis as a phosphate binder.We have previously shown that oral application of sevelamer prevents the bone loss and increases the bone volume in ovariectomized rats1.
Slobodan Vukičević   +11 more
core  

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients.

open access: yes, 2010
Sevelamer hydrochloride (HCl), a calcium-free phosphate binder, is increasingly used due to concerns related to calcium exposure and the development of vascular calcifications.
Amin, Nimisha   +4 more
core  

A Case of Crystal-Associated Colitis Caused by Sevelamer

open access: yesAnnals of Internal Medicine: Clinical Cases
Sevelamer, a calcium-free phosphate binder used in chronic kidney disease, can lead to gastrointestinal side effects and, rarely, crystal-associated colitis. We present a case of sevelamer-induced colitis in a 66-year-old man with end-stage renal disease.
Ryan Plunkett   +5 more
doaj   +1 more source

PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.

open access: yesPLoS ONE, 2017
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated.
Atsushi Yaguchi   +3 more
doaj   +1 more source

Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients

open access: yes, 2008
Disturbances in mineral metabolism play a central role in the development of renal bone disease. In a 54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare the effects of sevelamer hydrochloride and calcium carbonate on ...
Gil, C   +25 more
core   +1 more source

Meta analysis of efficiency and safety of sevelamer in the treatment of hyperphosphatemia in patients with maintenance hemodialysis

open access: yesLinchuang shenzangbing zazhi, 2018
Objective The objective of this review is to inquire the efficiency and safety of sevelamer to decrease the level of serum phosphate of the patients with maintenance hemodialysis.Methods According to the strict inclusion and exclusion criteria we search ...
YANG Ling
doaj  

PILOTSTUDY TO EVALUATE THE EFFECT OF PHOSPHORUSBINDERS ON FGF23

open access: yesKidney Research and Clinical Practice, 2012
The Netherlands Fibroblast growth Factor 23 (FGF23) is independently associated with cardiovasculair outcome. A reduction of dietary phosphorus intake in healthy individuals leads to a decrease of FGF23.
A.Bouma de Krijger   +3 more
doaj   +1 more source

Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study

open access: yes, 2017
Aortic stiffening and aortic calcification are risk factors for cardiovascular events in hemodialysis (HD) patients, and these 2 risk factors are interrelated.
Fodor E   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy